Market Insider

Take a look at some of the biggest movers in the premarket: Moderna (MRNA) – The drugmaker’s Covid-19 vaccine candidate produced neutralizing antibodies in all 45 patients involved in an early study, according to newly released data. Those antibodies were similar to those seen in patients who have recovered from Covid-19. UnitedHealth (UNH) – The
0 Comments
A view of Moderna headquarters on May 08, 2020 in Cambridge, Massachusetts. Moderna was given FDA approval to continue to phase 2 of Coronavirus (COVID-19) vaccine trials with 600 participants. Maddie Meyer | Getty Images Check out the companies making headlines in midday trading.  Moderna — Moderna shares jumped 10% after the data released by
0 Comments
The Norwegian Cruise Line Norwegian Bliss cruise ship passes through John Hopkins Inlet in Glacier Bay, Alaska, July 11, 2019. Tim Rue | Bloomberg | Getty Images Check out the companies making headlines after the bell:  Moderna — Shares of Moderna whipsawed in extended trading after rising nearly 7% earlier Wednesday. The stock has been on
0 Comments
Business spending showed some signs of green shoots in June, as manufacturers bought more equipment and spending shifted away from stay-at-home sectors to ones that could rebound in a reopening economy,  according to Cortera, a software company which analyzes business-to-business credit transactions. But overall June spending was still depressed, down 10.9% from the same month
0 Comments
Check out the companies making headlines before the bell Thursday: Walgreens Boots Alliance (WBA) — The pharmacy operator fell more than 3% in the premarket on weaker-than-expected results for its fiscal third quarter. Walgreens reported earnings per share of 83 cents, well below a FactSet estimate of $1.19 per share. The company’s fiscal-year earnings guidance
0 Comments
A customer leaves an ATM at a Wells Fargo branch in Denver. Rick Wilking | Reuters Check out the companies making headlines in midday trading:  Gilead Sciences — Gilead gained 2.1% after saying its coronavirus treatment candidate drug, remdesivir, was associated with an improvement in clinical recovery and a 62% reduction in the risk of mortality compared
0 Comments